Amgen Inc. vs Intel Corporation: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Intel Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Intel Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Intel Corporation is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $52.9B for Intel Corporation, while their respective market capitalizations stand at $228.2B and $639.9B. Both Amgen Inc. and Intel Corporation are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Intel Corporation: Intel was founded in 1968 by Robert Noyce and Gordon Moore and became the defining PC chip company through the x86 architecture, the 'Intel Inside' brand, and its partnership with Microsoft. It missed the smartphone shift, suffered years of 10nm and 7nm delays, and lost Apple's Mac business to Apple silicon in 2020. Pat Gelsinger's IDM 2.0 plan (2021-2024) rebuilt the process roadmap at high cost. Lip-Bu Tan, CEO since March 2025, has focused on cost cuts, customer focus, and new capital from the U.S. government, Nvidia, and SoftBank.

Amgen Inc. and Intel Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Intel Corporation.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Intel Corporation business model: Intel is an integrated device manufacturer (IDM): it designs chips and runs its own fabs in Oregon, Arizona, New Mexico, Ireland, and Israel. Since 2024 it reports two halves. Intel Products (client CPUs, Xeon data-center CPUs, AI accelerators) sells to OEMs, hyperscalers, and enterprises. Intel Foundry manufactures wafers and packages for Intel Products and for external customers, competing with TSMC and Samsung. Intel also owns a majority of Mobileye (ADAS chips) and kept a 49% stake in Altera after selling 51% to Silver Lake in September 2025.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Intel Corporation.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Intel Corporation competitive advantage: Intel's advantages are the installed base of x86 software, deep OEM and enterprise relationships, leading-edge U.S. fabs, and advanced packaging (EMIB, Foveros) that AI chip designers increasingly need. Its role as the main American maker of leading-edge logic chips also brings policy support: the U.S. government became its largest shareholder in August 2025.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Intel Corporation each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Intel Corporation growth strategy: Under Lip-Bu Tan, Intel has cut layers and headcount, slowed some fab projects such as Ohio, and tied foundry spending to committed customer demand. Growth bets for 2026-2027 are Xeon CPUs for AI servers (DCAI revenue rose 59% year over year in Q2 2026), Panther Lake AI PC processors on Intel 18A, advanced packaging for third-party AI chips, custom x86 parts co-developed with Nvidia, and winning external customers for the 14A node.

A closer look at the financial trajectory of Amgen Inc. and Intel Corporation rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Intel Corporation: Intel's revenue peaked at $79.0 billion in 2021 and fell to $53.1 billion in 2024, when it posted an $18.8 billion net loss driven by restructuring and impairments. FY2025 revenue was $52.9 billion with a much smaller $267 million net loss, and the year ended with $37.4 billion in cash and short-term investments. Q2 2026 revenue rose 25% to $16.1 billion with a 41.8% non-GAAP gross margin and $0.42 non-GAAP EPS. GAAP net loss for the quarter was $11.0 billion, almost all from a $12.5 billion non-cash mark-to-market charge on shares escrowed for the U.S. Department of Commerce. Intel guided Q3 2026 revenue to $15.8-16.8 billion.